Loading
Four cancer medicines are among the drugs selected for the third round of Medicare price negotiation, with prices due from 1 January 2028: Erleada (apalutamide), Kisqali (ribociclib), Verzenio (abemaciclib) and Lenvima (lenvatinib). The negotiated prices had not been published in CMS's data file by November 2026.
United States, Medicare Drug Price Negotiation Program, third cycle. CMS's data file of 2 November 2026 lists fourteen drugs for initial price applicability year 2028, each with an effective date of 1 January 2028. Four are cancer medicines: Erleada (apalutamide), Kisqali (ribociclib), Verzenio (abemaciclib) and Lenvima (lenvatinib). The file gives no maximum fair price for any 2028 drug yet; the price columns are blank.
Showing the molecule this term concerns: Apalutamide.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares the tags law, us.
Shares the tags law, us.
Shares the tags law, us.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/